Literature DB >> 12445202

The phosphotidyl inositol 3-kinase/Akt signal pathway is involved in interleukin-6-mediated Mcl-1 upregulation and anti-apoptosis activity in basal cell carcinoma cells.

S H Jee1, H C Chiu, T F Tsai, W L Tsai, Y H Liao, C Y Chu, M L Kuo.   

Abstract

Dysregulation of interleukin-6 has been reported to be associated with various types of tumors, and interleukin-6 plays an important part in regulating apoptosis in many types of cells. Previously, Mcl-1 was shown to be significantly increased in interleukin-6-overexpressed basal cell carcinoma cells and conferred on them anti-apoptotic activity. The aim of this study was to investigate which signaling pathway is involved in the anti-apoptotic effect of interleukin-6 on basal cell carcinoma cells. Here we show that the addition of recombinant 100 ng per ml interleukin-6 to basal cell carcinoma cells induced a 2.3-fold increase in the level of Mcl-1 protein in basal cell carcinoma cells. Transfection with dominant-negative STAT3 (STAT3F) into inter-leukin-6-treated basal cell carcinoma cells caused a decrease of phosphotyrosyl STAT3 but did not alter Mcl-1 protein levels; however, AG490, a Janus tyrosine kinase inhibitor, was capable of inhibiting the interleukin-6-induced elevation of Mcl-1 protein. Next, interleukin-6 stimulation elicited extracellular signal-regulated kinase activation in basal cell carcinoma cells, and the mitogen-activated protein kinase inhibitor, PD98059, could affect this response without affecting the interleukin-6-medi-ated Mcl-1 upregulation. Use of the two phosphotidyl inositol 3-kinase inhibitors, LY294002 and wortmannin, to check whether this pathway is involved in Mcl-1 upregulation by interleukin-6, we found that the phosphotidyl inositol 3-kinase inhibitors completely attenuated the interleukin-6-induced Mcl-1 upregulation. Furthermore, in the interleukin-6-overexpressing basal cell carcinoma cell clone, dominant-negative Akt also significantly reduced the increased level of Mcl-1. Interestingly, Janus tyrosine kinase inhibitor, AG490, treatment strongly blocked the phosphotidyl inositol 3-kinase pathway activation, as evidenced by the decrease in phospho-Akt level. Blockage of phosphotidyl inositol 3-kinase/Akt pathway abolished the interleukin-6-mediated anti-apoptotic activity in ultraviolet B treated cells. Unexpectedly, without ultraviolet B irradiation, STAT3F transfection also induced a significant apoptosis in basal cell carcinoma/interleukin-6 cells. Taken together, our data suggest that both the phosphotidyl inositol 3-kinase/Akt and STAT3 pathways are potentially involved in interleukin-6-mediated cell survival activity in basal cell carcinoma cells; however, the upregulation of the anti-apoptotic Mcl-1 protein by interleukin-6 is mainly through the Janus tyrosine kinase/phosphotidyl inositol 3-kinase/Akt, but not the STAT3 pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445202     DOI: 10.1046/j.1523-1747.2002.19503.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  16 in total

Review 1.  Interleukin-6 and insulin sensitivity: friend or foe?

Authors:  A L Carey; M A Febbraio
Journal:  Diabetologia       Date:  2004-07-07       Impact factor: 10.122

2.  Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer.

Authors:  Christopher Johnson; Yuyan Han; Nathan Hughart; Jennifer McCarra; Gianfranco Alpini; Fanyin Meng
Journal:  Transl Gastrointest Cancer       Date:  2012-04-01

3.  Integrating pathway analysis and genetics of gene expression for genome-wide association study of basal cell carcinoma.

Authors:  Mingfeng Zhang; Liming Liang; Nilesh Morar; Anna L Dixon; G Mark Lathrop; Jun Ding; Miriam F Moffatt; William O C Cookson; Peter Kraft; Abrar A Qureshi; Jiali Han
Journal:  Hum Genet       Date:  2011-10-18       Impact factor: 4.132

4.  Oncostatin M treatment increases the responsiveness toward cisplatin-based chemoradiotherapy in cervical cancer cells in a STAT3-dependent manner.

Authors:  Russalina Stroeder; Barbara Walch-Rückheim; Jil Fischbach; Ingolf Juhasz-Böss; Christian Rübe; Erich-Franz Solomayer; Sigrun Smola
Journal:  Oncol Lett       Date:  2018-06-18       Impact factor: 2.967

5.  Conditioned media from mouse osteosarcoma cells promote MC3T3-E1 cell proliferation using JAKs and PI3-K/Akt signal crosstalk.

Authors:  Kanji Mori; Frederic Blanchard; Celine Charrier; Severine Battaglia; Kosei Ando; Laurence Duplomb; Leonard D Shultz; Francoise Redini; Dominique Heymann
Journal:  Cancer Sci       Date:  2008-10-18       Impact factor: 6.716

6.  Interleukin-6 inhibits apoptosis of exocrine gland tissues under inflammatory conditions.

Authors:  Jing Zhou; Jun-O Jin; Ekta S Patel; Qing Yu
Journal:  Cytokine       Date:  2015-08-05       Impact factor: 3.861

Review 7.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Authors:  Peter C Heinrich; Iris Behrmann; Serge Haan; Heike M Hermanns; Gerhard Müller-Newen; Fred Schaper
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

Review 8.  Role of interleukin-6 in cancer progression and therapeutic resistance.

Authors:  Neeraj Kumari; B S Dwarakanath; Asmita Das; Anant Narayan Bhatt
Journal:  Tumour Biol       Date:  2016-06-03

9.  Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes.

Authors:  Fanyin Meng; Yoko Yamagiwa; Yoshiyuki Ueno; Tushar Patel
Journal:  J Hepatol       Date:  2005-12-13       Impact factor: 25.083

10.  Acute myotube protein synthesis regulation by IL-6-related cytokines.

Authors:  Song Gao; J Larry Durstine; Ho-Jin Koh; Wayne E Carver; Norma Frizzell; James A Carson
Journal:  Am J Physiol Cell Physiol       Date:  2017-08-02       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.